scispace - formally typeset
Journal ArticleDOI

Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II

Reads0
Chats0
TLDR
The natural progression of MPS II manifests as 2 divergent and distinct neurologic phenotypes with similar somatic disease, which may have primary neural parenchymal disease with cognitive involvement or may maintain normal cognitive abilities.
Abstract
OBJECTIVE: Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by insufficiency of the iduronate-2-sulfatase enzyme, which results in excess heparan and dermatan sulfates within the lysosomes of various tissues and organs, including the central nervous system. The purpose of this study was to investigate the natural progression of neurologic disease in a large cohort of patients evaluated with standardized testing at a single institution. METHODS: During the period of December 2002 to October 2010, patients with MPS II were referred to the Program for Neurodevelopmental Function in Rare Disorders. A retrospective review of patient data was performed, which included the use of detailed questionnaires that addressed medical history, notes from previous health care providers, and the results of a multidisciplinary evaluation that lasted 4 to 6 hours and was performed by a team of neurodevelopmental pediatricians, speech pathologists, psychologists, audiologists, psychometricians, and occupational and physical therapists. Patients were evaluated annually for management of disease progression. RESULTS: A total of 50 male patients with MPS II were evaluated over 152 encounters. Two distinct subgroups of children were identified. One subset of patients had normal cognitive, speech and language, and adaptive functions whereas the other showed a dramatic decline in these areas. All patients developed fine and gross motor deficits. CONCLUSION: The natural progression of MPS II manifests as 2 divergent and distinct neurologic phenotypes with similar somatic disease. Patients may have primary neural parenchymal disease with cognitive involvement or may maintain normal cognitive abilities.

read more

Citations
More filters
Journal ArticleDOI

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

TL;DR: Developmental quotient and cortical gray matter volume are sensitive markers of disease progression in MPS IIIA, and may have utility as clinical endpoints in treatment trials.
Journal ArticleDOI

Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders

TL;DR: The anatomical and pathophysiological CNS changes accompanying HS accumulation as well as the mechanisms believed to cause CNS abnormalities in MPS patients are discussed.
Journal ArticleDOI

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.

TL;DR: The history of the disease during this century is summarized through clinical and laboratory evaluations that allowed its definition, its correct diagnosis, a partial comprehension of its pathogenesis, and the proposition of therapeutic protocols.
Journal ArticleDOI

Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.

TL;DR: ApoEII mediated complete normalization of brain pathology and behavior, providing significantly enhanced correction compared to IDS, and brain‐targeted hematopoietic stem cell gene therapy provides a promising therapy for MPS II patients.
Journal ArticleDOI

Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms

TL;DR: The appearance and progression of neurological signs and symptoms in patients with MPS I, II, and III are described, based on presentations and discussions among an international group of experts during a meeting on the brain in MPS on April 28-30, 2016, and additional literature searches on this subject.
References
More filters
Book

The Metabolic and Molecular Bases of Inherited Disease

TL;DR: In this paper, the authors present a list of disorders of MITOCHONDRIAL FUNCTION, including the following: DISORDERS OF MIOCHONDRIC FERTILITY XIX, XVI, XIX.
Journal ArticleDOI

Prevalence of lysosomal storage disorders.

TL;DR: There was no significant increase in the rate of either clinical diagnoses or prenatal diagnoses of lysosomal storage disorders during the study period, and as a group, they are relatively common and represent an important health problem in Australia.
Journal ArticleDOI

The frequency of lysosomal storage diseases in The Netherlands

TL;DR: The relative frequency and the birth prevalence of lysosomal storage diseases in The Netherlands based on all 963 enzymatically confirmed cases diagnosed during the period 1970–1996 is calculated.
Journal ArticleDOI

Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease

TL;DR: Infants who underwent transplantation before the development of symptoms showed progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills, but a few had mild- to-moderate delays in expressive language and mild-to-severe delays in gross motor function.
Related Papers (5)